Abstract
Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). Methods: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks. Patients reported diarrhea and/or flushing symptom severity and frequency and short-acting SC octreotide rescue therapy daily using an Interactive Voice/Web Response System. To evaluate the efficacy of lanreotide compared with placebo, the novel primary endpoint of patient-determined use of SC octreotide rescue therapy for breakthrough symptoms was used as a surrogate for symptom control. Clinically meaningful patient-reported treatment benefit was examined using daily patient-reported symptoms of diarrhea and flushing. Results: Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide. Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares LS mean difference-19.1, P =.0477 and-6.9, P =.4332, respectively). The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference-14.6, P =.0140 and-10.9, P =.0746, respectively). The transition from octreotide to lanreotide was generally well-tolerated. Conclusion: Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 243-255 |
| Number of pages | 13 |
| Journal | Endocrine Practice |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
LANREOTIDE THERAPY in CARCINOID SYNDROME : PROSPECTIVE ANALYSIS of PATIENT-REPORTED SYMPTOMS in PATIENTS RESPONSIVE to PRIOR OCTREOTIDE THERAPY and PATIENTS NAÏVE to SOMATOSTATIN ANALOGUE THERAPY in the ELECT PHASE 3 STUDY. / Fisher, George A.; Wolin, Edward M.; Liyanage, Nilani; Lowenthal, Susan Pitman; Mirakhur, Beloo; Pommier, Rodney; Shaheen, Montaser; Vinik, Aaron I.
In: Endocrine Practice, Vol. 24, No. 3, 01.03.2018, p. 243-255.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - LANREOTIDE THERAPY in CARCINOID SYNDROME
T2 - PROSPECTIVE ANALYSIS of PATIENT-REPORTED SYMPTOMS in PATIENTS RESPONSIVE to PRIOR OCTREOTIDE THERAPY and PATIENTS NAÏVE to SOMATOSTATIN ANALOGUE THERAPY in the ELECT PHASE 3 STUDY
AU - Fisher, George A.
AU - Wolin, Edward M.
AU - Liyanage, Nilani
AU - Lowenthal, Susan Pitman
AU - Mirakhur, Beloo
AU - Pommier, Rodney
AU - Shaheen, Montaser
AU - Vinik, Aaron I.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). Methods: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks. Patients reported diarrhea and/or flushing symptom severity and frequency and short-acting SC octreotide rescue therapy daily using an Interactive Voice/Web Response System. To evaluate the efficacy of lanreotide compared with placebo, the novel primary endpoint of patient-determined use of SC octreotide rescue therapy for breakthrough symptoms was used as a surrogate for symptom control. Clinically meaningful patient-reported treatment benefit was examined using daily patient-reported symptoms of diarrhea and flushing. Results: Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide. Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares LS mean difference-19.1, P =.0477 and-6.9, P =.4332, respectively). The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference-14.6, P =.0140 and-10.9, P =.0746, respectively). The transition from octreotide to lanreotide was generally well-tolerated. Conclusion: Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.
AB - Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). Methods: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks. Patients reported diarrhea and/or flushing symptom severity and frequency and short-acting SC octreotide rescue therapy daily using an Interactive Voice/Web Response System. To evaluate the efficacy of lanreotide compared with placebo, the novel primary endpoint of patient-determined use of SC octreotide rescue therapy for breakthrough symptoms was used as a surrogate for symptom control. Clinically meaningful patient-reported treatment benefit was examined using daily patient-reported symptoms of diarrhea and flushing. Results: Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide. Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares LS mean difference-19.1, P =.0477 and-6.9, P =.4332, respectively). The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference-14.6, P =.0140 and-10.9, P =.0746, respectively). The transition from octreotide to lanreotide was generally well-tolerated. Conclusion: Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.
UR - http://www.scopus.com/inward/record.url?scp=85044121266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044121266&partnerID=8YFLogxK
U2 - 10.4158/EP172000.OR
DO - 10.4158/EP172000.OR
M3 - Article
C2 - 29547049
AN - SCOPUS:85044121266
VL - 24
SP - 243
EP - 255
JO - Endocrine Practice
JF - Endocrine Practice
SN - 1530-891X
IS - 3
ER -